ArticleBreast cancer research : BCR2024

siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.

Prakash Chaudhary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.